Provectus Biopharmaceuticals, Inc. (PVCT)
USD 0.1
(-3.01%)
USD 0.1
(-3.01%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -1.14 Million USD | -223.38% |
| 2022 | 925.26 Thousand USD | 1083.04% |
| 2021 | -94.12 Thousand USD | 70.15% |
| 2020 | -315.36 Thousand USD | 58.3% |
| 2019 | -756.36 Thousand USD | -10.38% |
| 2018 | -685.21 Thousand USD | 95.01% |
| 2017 | -13.72 Million USD | 44.02% |
| 2016 | -24.51 Million USD | 0.58% |
| 2015 | -24.65 Million USD | 99.8% |
| 2014 | -12.62 Billion USD | 3.06% |
| 2013 | -13.02 Billion USD | 9.13% |
| 2012 | -14.33 Billion USD | -246.9% |
| 2011 | 9.75 Billion USD | 47265.67% |
| 2010 | -20.69 Million USD | -67.88% |
| 2009 | -12.32 Million USD | 0.0% |
| 2008 | - USD | 100.0% |
| 2007 | -10.31 Million USD | -2091811.76% |
| 2006 | 493.00 USD | -83.43% |
| 2005 | 2976.00 USD | -85.88% |
| 2004 | 21.07 Thousand USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | -100.0% |
| 2000 | 1.00 USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 252.76 Thousand USD | 7.17% |
| 2024 Q1 | 235.84 Thousand USD | 98.39% |
| 2023 Q4 | 118.88 Thousand USD | 76.11% |
| 2023 Q2 | 148.4 Thousand USD | -22.59% |
| 2023 Q1 | 191.72 Thousand USD | 26.25% |
| 2023 FY | 548.78 Thousand USD | -40.69% |
| 2023 Q3 | 67.5 Thousand USD | -54.52% |
| 2022 Q1 | 160 Thousand USD | 814.61% |
| 2022 Q4 | 151.86 Thousand USD | -49.59% |
| 2022 Q3 | 301.26 Thousand USD | -3.48% |
| 2022 FY | 925.26 Thousand USD | 1083.04% |
| 2022 Q2 | 312.13 Thousand USD | 95.08% |
| 2021 Q4 | -22.39 Thousand USD | 11.46% |
| 2021 Q2 | -23.22 Thousand USD | 0.0% |
| 2021 FY | -94.12 Thousand USD | 70.15% |
| 2021 Q3 | -25.28 Thousand USD | -8.9% |
| 2021 Q1 | -23.22 Thousand USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2020 FY | -315.36 Thousand USD | 58.3% |
| 2020 Q3 | - USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 FY | -756.36 Thousand USD | -10.38% |
| 2018 Q2 | -2.32 Million USD | 19.83% |
| 2018 FY | -685.21 Thousand USD | 95.01% |
| 2018 Q4 | - USD | 100.0% |
| 2018 Q1 | -2.9 Million USD | 0.0% |
| 2018 Q3 | -2.99 Million USD | -28.52% |
| 2017 Q3 | -3.11 Million USD | 5.57% |
| 2017 Q4 | - USD | 100.0% |
| 2017 Q1 | -4.39 Million USD | -5274.32% |
| 2017 FY | -13.72 Million USD | 44.02% |
| 2017 Q2 | -3.3 Million USD | 24.9% |
| 2016 Q2 | -5.04 Million USD | 40.7% |
| 2016 Q1 | -8.5 Million USD | -5696.85% |
| 2016 Q3 | -5.77 Million USD | -14.51% |
| 2016 Q4 | 85 Thousand USD | 101.47% |
| 2016 FY | -24.51 Million USD | 0.58% |
| 2015 Q3 | -5.77 Million USD | -25.85% |
| 2015 Q1 | -4.62 Million USD | -210.58% |
| 2015 FY | -24.65 Million USD | 99.8% |
| 2015 Q2 | -4.59 Million USD | 0.62% |
| 2015 Q4 | 152 Thousand USD | 102.63% |
| 2014 FY | -12.62 Billion USD | 3.06% |
| 2014 Q4 | 4.17 Million USD | 209.22% |
| 2014 Q1 | -4.38 Million USD | 0.0% |
| 2014 Q2 | -4.15 Million USD | 5.06% |
| 2014 Q3 | -3.82 Million USD | 8.03% |
| 2013 FY | -13.02 Billion USD | 9.13% |
| 2013 Q4 | - USD | 100.0% |
| 2013 Q3 | -3.65 Million USD | -11.05% |
| 2013 Q2 | -3.28 Million USD | -1.24% |
| 2013 Q1 | -3.24 Million USD | 0.0% |
| 2012 Q2 | -4.28 Million USD | -1.91% |
| 2012 FY | -14.33 Billion USD | -246.9% |
| 2012 Q1 | -4.2 Million USD | -100.04% |
| 2012 Q4 | - USD | 100.0% |
| 2012 Q3 | -3.59 Million USD | 16.12% |
| 2011 Q4 | 9.75 Billion USD | 130740.17% |
| 2011 Q1 | -4.19 Million USD | 79.73% |
| 2011 FY | 9.75 Billion USD | 47265.67% |
| 2011 Q2 | - USD | 100.0% |
| 2011 Q3 | -7.47 Million USD | 0.0% |
| 2010 FY | -20.69 Million USD | -67.88% |
| 2010 Q4 | -20.69 Million USD | -178.14% |
| 2010 Q3 | -7.43 Million USD | -34.73% |
| 2010 Q2 | -5.52 Million USD | -92.53% |
| 2010 Q1 | -2.86 Million USD | 69.97% |
| 2009 Q4 | -9.55 Million USD | -238.33% |
| 2009 FY | -12.32 Million USD | 0.0% |
| 2009 Q1 | 48.76 Thousand USD | 0.0% |
| 2009 Q2 | - USD | -100.0% |
| 2009 Q3 | -2.82 Million USD | 0.0% |
| 2008 Q3 | -2.42 Million USD | 10.63% |
| 2008 Q4 | - USD | 100.0% |
| 2008 FY | - USD | 100.0% |
| 2008 Q1 | -2.39 Million USD | 0.0% |
| 2008 Q2 | -2.71 Million USD | -13.31% |
| 2007 FY | -10.31 Million USD | -2091811.76% |
| 2007 Q1 | -2.46 Million USD | -49246380.0% |
| 2007 Q2 | -2.39 Million USD | 2.86% |
| 2007 Q3 | -2.78 Million USD | -16.58% |
| 2007 Q4 | - USD | 100.0% |
| 2006 Q4 | 5.00 USD | -94.95% |
| 2006 FY | 493.00 USD | -83.43% |
| 2006 Q1 | 247.00 USD | -37.63% |
| 2006 Q2 | 142.00 USD | -42.51% |
| 2006 Q3 | 99.00 USD | -30.28% |
| 2005 Q3 | 139.00 USD | -76.95% |
| 2005 FY | 2976.00 USD | -85.88% |
| 2005 Q4 | 396.00 USD | 184.89% |
| 2005 Q1 | 1838.00 USD | -82.95% |
| 2005 Q2 | 603.00 USD | -67.19% |
| 2004 Q1 | 12.62 Thousand USD | 0.0% |
| 2004 FY | 21.07 Thousand USD | 0.0% |
| 2004 Q4 | 10.78 Thousand USD | 3261.58% |
| 2004 Q3 | -341.00 USD | -46.35% |
| 2004 Q2 | -233.00 USD | -101.84% |
| 2003 Q1 | - USD | 100.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q4 | -5000.00 USD | 0.0% |
| 2002 Q3 | - USD | -100.0% |
| 2002 Q2 | 5000.00 USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2001 Q1 | 1.00 USD | 0.0% |
| 2001 Q3 | 1.00 USD | 0.0% |
| 2001 Q2 | 1.00 USD | 0.0% |
| 2001 FY | - USD | -100.0% |
| 2001 Q4 | - USD | -100.0% |
| 2000 FY | 1.00 USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | -46704.92% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 109.752% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | -257.292% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 100.958% |
| Qrons Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 95.575% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | -2265.511% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | -818.763% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 107.611% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 36901.161% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 111.656% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 1836.812% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | -3242.817% |
| Mesoblast Limited | -35.16 Million USD | 96.754% |
| Marizyme, Inc. | 457.7 Thousand USD | 349.414% |
| Genus plc | 178.7 Million USD | 100.639% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 100.519% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 1934.558% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 378.32% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | -10277.927% |
| ContraFect Corporation | -154 Thousand USD | -641.281% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | -2183.144% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 1587.177% |
| IMV Inc. | -962.29 Thousand USD | -18.63% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | -194.598% |
| MultiCell Technologies, Inc. | 49.32 USD | 2314722.871% |
| ONE Bio Corp. | 20.12 Million USD | 105.672% |
| Accustem Sciences Inc. | - USD | Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 102.835% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | 2434.503% |
| Q BioMed Inc. | -8988.00 USD | -12601.068% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 104.04% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | -7301.271% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 102.574% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 1730.817% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | -22952.746% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 912.507% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | -1070.663% |
| GB Sciences, Inc. | -624.00 USD | -182844.231% |
| Alpha Cognition Inc. | -86.02 Thousand USD | -1226.977% |
| HST Global, Inc. | - USD | Infinity% |
| CSL Limited | 7.56 Billion USD | 100.015% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Halberd Corporation | -208.00 USD | -548732.692% |
| Enzolytics Inc. | 30.7 Thousand USD | 3817.507% |
| Agentix Corp. | - USD | Infinity% |
| Resverlogix Corp. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 336.628% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | 1.1 Billion USD | 100.103% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | -121.876% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 284.905% |
| Zenith Capital Corp. | - USD | Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 100.279% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | -12790.379% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | -1261.462% |
| Kadimastem Ltd | -630.13 Thousand USD | -81.162% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 215.546% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 111.878% |
| BioStem Technologies, Inc. | 15.42 Million USD | 107.401% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | - USD | Infinity% |
| LadRx Corporation | -11.83 Thousand USD | -9545.729% |
| Cell Source, Inc. | - USD | Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 746.563% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 746.563% |
| NovAccess Global Inc. | - USD | Infinity% |
| Affymax, Inc. | 1.35 Million USD | 184.116% |
| Itoco Inc. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| CytoDyn Inc. | -29 Thousand USD | -3836.455% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 353.658% |
| SYBLEU INC | 11.69 Thousand USD | 9860.363% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 124.774% |
| Bioxytran, Inc. | -8285.00 USD | -13678.781% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | -206.051% |
| Neutra Corp. | 14.33 Thousand USD | 8063.53% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | -1292.161% |
| PureTech Health plc | -1.6 Million USD | 28.785% |
| Coeptis Therapeutics, Inc. | -1 Million USD | -14.016% |
| IXICO plc | 3.27 Million USD | 134.91% |
| IntelGenx Technologies Corp. | -694 Thousand USD | -64.492% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 36.261% |
| CSL Limited | 7.7 Billion USD | 100.015% |
| Cellectis S.A. | 18 Thousand USD | 6442.067% |